Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experienceDE GIORGI, U; DEMIRER, T; WANDT, H et al.Annals of oncology. 2005, Vol 16, Num 1, pp 146-151, issn 0923-7534, 6 p.Article

Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatmentRAMOS, M; GONZALEZ-AGEITOS, A; AMENEDO, M et al.Journal of chemotherapy. 2003, Vol 15, Num 2, pp 192-197, issn 1120-009X, 6 p.Article

Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapyNATHER, Andreas; MAYERHOFER, Klaus; GRIMM, Christoph et al.Anticancer research. 2003, Vol 23, Num 3C, pp 2991-2994, issn 0250-7005, 4 p.Article

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysisKIM, H. S; KIM, H. J; KIM, S. Y et al.Annals of oncology. 2013, Vol 24, Num 11, pp 2850-2854, issn 0923-7534, 5 p.Article

Second-line chemotherapy for patients with advanced gastric cancer : who may benefit?CATALANO, V; GRAZIANO, F; TONINI, G et al.British journal of cancer. 2008, Vol 99, Num 9, pp 1402-1407, issn 0007-0920, 6 p.Article

Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failureHIRAO, Ken; HIRASAKI, Shoji; TSUZUKI, Takao et al.Internal medicine (Tokyo. 1992). 2004, Vol 43, Num 2, pp 106-110, issn 0918-2918, 5 p.Article

A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapyKANAGAVEL, D; POKATAEV, I. A; FEDYANIN, M. Y et al.Annals of oncology. 2010, Vol 21, Num 9, pp 1779-1785, issn 0923-7534, 7 p.Article

A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study)KODERA, Yasuhiro; ITO, Seiji; FUJIWARA, Michitaka et al.Anticancer research. 2007, Vol 27, Num 4C, pp 2667-2671, issn 0250-7005, 5 p.Article

Second-line chemotherapy in advanced pancreatic carcinoma : A multicenter survey of the Gruppo Oncologico italia meridionale on the activity and safety of the FOLFOX4 regimen in clinical practiceGEBBIA, V; MAIELLO, E; DI CRISTINA, L et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi124-vi127, SUP6Conference Paper

Multicyclic dose-intensive chemotherapy supported by autologous blood progenitor cell transplantation for relapsed small cell lung cancerFUJIMOTO, Nobukazu; UEOKA, Hiroshi; HARADA, Mine et al.Anticancer research. 2003, Vol 23, Num 5B, pp 4229-4232, issn 0250-7005, 4 p.Article

Second-Line Docetaxel plus Cisplatin for Advanced Gastric Cancer Showing Resistance to S-1TAKAGAWA, R; KUNISAKI, C; MAKINO, H et al.Journal of chemotherapy (Testo stampato). 2011, Vol 23, Num 1, pp 44-48, issn 1120-009X, 5 p.Article

Gemcitabine and Vinorelbine in Pemetrexed-Pretreated Patients With Malignant Pleural MesotheliomaZUCALI, Paolo A; CERESOLI, Giovanni L; GARASSINO, Isabella et al.Cancer. 2008, Vol 112, Num 7, pp 1555-1561, issn 0008-543X, 7 p.Article

Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer : A phase II studyROSATI, G; BILANCIA, D; GERMANO, D et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi128-vi132, SUP6Conference Paper

Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?ODRAZKA, Karel; VACULIKOVA, Miloslava; DOLEZEL, Martin et al.Oncology reports. 2005, Vol 14, Num 4, pp 1077-1081, issn 1021-335X, 5 p.Article

ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II studySMIT, E. F; MATTSON, K; VON PAWEL, J et al.Annals of oncology. 2003, Vol 14, Num 3, pp 455-460, issn 0923-7534, 6 p.Article

Performance Status and Sensitivity to First-line Chemotherapy Are Significant Prognostic Factors in Patients With Recurrent Small Cell Lung Cancer Receiving Second-line ChemotherapyYOUNG HAK KIM; GOTO, Koichi; YOH, Kiyotaka et al.Cancer. 2008, Vol 113, Num 9, pp 2518-2523, issn 0008-543X, 6 p.Article

Optimal dose-finding study of Bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancerKOIZUMI, Wasaburo; TANABE, Satoshi; HIGUCHI, Katsuhiko et al.Anticancer research. 2006, Vol 26, Num 5B, pp 3797-3802, issn 0250-7005, 6 p.Article

A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung CancerKOTSAKIS, Athanasios; HATZIDAKI, Dora; AGELAKI, Sophia et al.Anticancer research. 2010, Vol 30, Num 10, pp 4335-4342, issn 0250-7005, 8 p.Article

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcomaREICHARDT, Peter; OECHSLE, Karin; PINK, Daniel et al.Investigational new drugs. 2003, Vol 21, Num 4, pp 481-486, issn 0167-6997, 6 p.Article

Is Resection of Colorectal Liver Metastases After a Second-Line Chemotherapy Regimen Justified?BROUQUET, Antoine; OVERMAN, Michael J; VAUTHEY, Jean-Nicolas et al.Cancer. 2011, Vol 117, Num 19, pp 4484-4492, issn 0008-543X, 9 p.Article

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaMANEGOLD, C; SYMANOWSKI, J; GATZEMEIER, U et al.Annals of oncology. 2005, Vol 16, Num 6, pp 923-927, issn 0923-7534, 5 p.Article

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisoloneKIM, B.-S; KIM, D.-W; KIM, N. K et al.Annals of oncology. 2009, Vol 20, Num 1, pp 121-128, issn 0923-7534, 8 p.Article

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II studyGEORGOULIAS, V; KOUROUSSIS, C; ARDAVANIS, A et al.British journal of cancer. 2004, Vol 91, Num 3, pp 482-488, issn 0007-0920, 7 p.Article

Evaluation of Oral Etoposide in Combination with Cisplatin for Patients with Recurrent Cervical Cancer: Long-term Follow-up Results of a Japanese Multicenter StudyWATANABE, Yoh; HOSHIAI, Hiroshi; NAKANISHI, Toru et al.Anticancer research. 2011, Vol 31, Num 9, pp 3063-3067, issn 0250-7005, 5 p.Article

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancerCULLEN, M. H; ZATLOUKAL, P; SÖRENSON, S et al.Annals of oncology. 2008, Vol 19, Num 5, pp 939-945, issn 0923-7534, 7 p.Article